LAMISIL
LOE ApproachingNDATOPICALCREAM
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMISIL (terbinafine) is a topical antifungal cream approved in 1992 for treating tinea pedis (athlete's foot). It is a small-molecule allylamine that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in fungal cell membranes. This mechanism differentiates it from azole competitors.
LOE Approaching
Product is approaching loss of exclusivity in a mature, low-growth category; expect modest team size and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
30 enrolled
Candidiasis, OralHIV Infections
Career Relevance
LAMISIL offers limited career growth due to LOE proximity and saturated competitive environment. Roles focus on defending market share, managing payer relationships, and planning generic transition rather than driving innovation or expansion.
Brand Manager
Worked on LAMISIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.